Compare ClearPoint Neuro Inc (CLPT) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? ClearPoint Neuro Inc trades at $16.07 (market cap $478.63M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.65. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | VEA | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | — |
52-Week High | $29.60 | $72.39 |
52-Week Low | $8.66 | $56.02 |
Enterprise Value | $506.63M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
VEA trades at $69.76, down 1.73% over the past day, with technical indicators signaling a bearish trend. The ETF offers broad exposure to developed international markets with a low expense ratio of 0.03% and a forward P/E of 17.7x, providing a valuation discount to US equities. Recent news highlights its outperformance versus US benchmarks and strong asset growth under Vanguard's management.
Outlook remains positive for long-term diversification given its cost efficiency and geographic reach, though near-term risks include central bank rate hikes and political uncertainty in key markets like the UK. The bearish technical setup suggests potential for further consolidation before resuming upward momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
